Department of Clinical Laboratory Diagnosis, People's Hospital of Juxian, Rizhao, Shandong, 276500, PR China.
Clinical laboratory, Maternity & Child Health Care Hospital of Laizhou, Laizhou, 261499, PR China.
Future Oncol. 2018 Sep;14(21):2139-2148. doi: 10.2217/fon-2018-0207. Epub 2018 Apr 26.
To study the expression profile of SLC22A16 in gastric cancer (GC), its prognostic value and the potential mechanisms of its upregulation.
PATIENTS & METHODS: A retrospective study was performed by using data in the Human Protein Atlas and The Cancer Genome Atlas-Stomach Cancer (STAD). Results: SLC22A16 was significantly upregulated in GC tissues compared with normal stomach tissues. SLC22A16 upregulation independently predicted poor overall survival (hazard ratio [HR]: 1.424, 95% CI: 1.169-1.735; p < 0.001) and recurrence-free survival (HR: 1.658, 95% CI: 1.292-2.128; p < 0.001) in early GC and poor overall survival (HR: 1.411, 95% CI: 1.137-1.752; p = 0.002) in advanced GC. SLC22A16 DNA hypomethylation might be a compensation for DNA loss to maintain SLC22A16 elevation in GC.
SLC22A16 might be a valuable prognostic marker in GC.
研究 SLC22A16 在胃癌（GC）中的表达谱、其预后价值及其上调的潜在机制。
本研究采用了人类蛋白质图谱和癌症基因组图谱-胃癌（STAD）的数据进行回顾性研究。结果：与正常胃组织相比，SLC22A16 在 GC 组织中明显上调。SLC22A16 的上调独立预测早期 GC 的总生存期（HR：1.424，95%CI：1.169-1.735；p<0.001）和无复发生存期（HR：1.658，95%CI：1.292-2.128；p<0.001）不良，晚期 GC 的总生存期不良（HR：1.411，95%CI：1.137-1.752；p=0.002）。SLC22A16 的 DNA 低甲基化可能是一种补偿性机制，以维持 GC 中 SLC22A16 的升高，以弥补 DNA 的丢失。
SLC22A16 可能是 GC 中一个有价值的预后标志物。
